Collaborating with Patients in Drug Development
Patients Are Members of the Drug Development Team
Chugai Pharmaceutical views patients as members of the drug development team.
Patients are the only individuals with real-life experience of living with their illness, and this perspective is essential to drug development.
Chugai Pharmaceutical collaborates with patients, medical institutions, and the MHLW to develop drugs and medical devices that truly satisfy patient needs.
Drug Development in Collaboration with Patients
Chugai Pharmaceutical promotes initiatives that incorporate the perspectives and voices of patients into drug development. This includes efforts to disseminate information about ongoing clinical trials, convey Chugai Pharmaceutical’s commitment to each participant, and reduce the burden on patients participating in trials.
Past clinical trials are introduced as examples. Chugai will continue to work with medical institutions to expand these clinical trial efforts and explore new ways to collaborate with patients.
Initiatives to Incorporate Patient Perspectives and Voices into Drug Development
[1] Clinical Trial Protocol Development
During the investigational plan phase, Chugai gathers input from patients based on their daily experiences with the disease, including their concerns about participating in clinical trials. These insights are reflected in the protocol before finalization.
[2] Informed Consent Form
Drafts of the Informed Consent Form are reviewed by multiple patients with the relevant condition. Patient feedback on unclear expressions or sections needing more detailed explanation is incorporated in the Informed Consent Form before finalization.
[3] Surveys for Clinical Trial Participants
We conduct surveys of participants after the clinical trial. The responses are carefully analyzed and used to improve the design of future clinical trials.
Initiatives to Share Chugai Pharmaceutical's Clinical Trial Information and Convey Our Gratitude to Participants
[1] Public Disclosure of Clinical Trial Information
To increase transparency, Chugai shares clinical trial information on this website for both patients and the general public. The names of the medical institutions conducting the clinical trials are also available in the Clinical Trial Information.
[2] Our Feelings of Gratitude and Letters to Clinical Trial Patients
While facing their own illnesses, our patients made the choice to participate in clinical trials. Through this website, Chugai Pharmaceutical would like to express its heartfelt gratitude to all patients who have taken part in our clinical trials.
In some studies, we also convey our appreciation by providing letters of thanks through medical institutions.
[3] Public Disclosure of Clinical Trial Results on jRCT
Chugai is working to share overall clinical trial results with patient participants through jRCT, a public platform in Japan that provides information on clinical research, including industry-sponsored trials.
Initiatives to Reduce the Burden on Patients who Participate in Clinical Trials
[1] Providing Flexible Care Options
Chugai supports home-based care options such as telemedicine, home nursing visits, and direct delivery of investigational drugs. In consultation with medical institution staff, patients may choose to complete checkups or tests in locations that minimize their burden.
[2] Use of Local Medical Institutions
Traditionally, patients had to visit designated clinical trial sites. Chugai now allows some tests to be conducted at nearby medical institutions to make participation more accessible.
<Drug Development Collaboration Guide［PDF 1.1MB］>
This guide was created to help everyone in the drug development team
to help deepen their understanding of the overall drug development process and clinical trials.
We have prepared these materials in the hope that by recognizing how your experiences contribute to progress in drug development, collaboration with pharmaceutical companies can be further enhanced.
You are now moving to an external website.